

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-10 (Canceled)

Claim 11 (Currently Amended): A method for ~~preventing~~ inhibiting or treating[[:]] neointimal proliferation and thickening and/or restenosis and/or vascular occlusion following vascular injury, ~~or~~

~~manifestations of chronic rejection in a recipient of organ or tissue transplant, or acute or chronic rejection in a recipient of organ or tissue xenograft transplant[[:]]~~

said method comprising: administering to the patient an effective amount of 40-O-(2-hydroxy)ethyl-rapamycin with an effective amount of a second agent selected from the group consisting of a cyclosporin or an immunosuppressive analog thereof, an ascomycin or immunosuppressive analog thereof, a corticosteroid, cyclophosphamide, azathioprene, methotrexate, brequinar, leflunomide, mizoribine, mycophenolic acid, mycophenolate mofetil, 15-deoxysperguatine, immunosuppressive monoclonal antibodies, and CTLA4-Ig.

Claim 12 (Previously Presented): The method of Claim 11 wherein the second agent is cyclosporin A, cyclosporin G, FK-506 or monoclonal antibodies to leukocyte receptors or to their ligands.

Claim 13 (Previously Presented): The method of Claim 11 wherein the second agent is monoclonal antibodies to MHC, CD2, CD3, CD4, CD7, CD25, CD28, B7, CD45, CD58, or to ligands thereof.

Claim 14 (Previously Presented): The method of Claim 13 wherein the second agent is monoclonal antibodies to CD3.

Claim 15 (Previously Prevented): The method of Claim 11 wherein the second agent is cyclosporin A.

Claim 16 (Previously Presented): The method of Claim 11 wherein the second agent is cyclosporin G.

Claim 17 (Previously Presented): The method of Claim 11 wherein the second agent is mycophenolic acid.

Claim 18 (Previously Presented): The method of Claim 11 wherein the second agent is CTLA4Ig.

Claim 19 (Previously Presented): The method of Claim 11 wherein the second agent is mycophenolate mofetil.

Claim 20 (Currently Amended): A method for ~~preventing~~ inhibiting or treating[[:]] neointimal proliferation and thickening and/or restenosis and/or vascular occlusion following vascular injury[[:]] said method comprising:

administering to the patient an effective amount of 40-O-(2-hydroxy)ethyl-rapamycin with an effective amount of a second agent selected from the group consisting of a cyclosporin or an immunosuppressive analog thereof, an ascomycin or immunosuppressive analog thereof, a corticosteroid, cyclophosphamide, azathioprene, methotrexate, brequinar, leflunomide, mizoribine, mycophenolic acid, mycophenolate

mofetil, 15-deoxysperguatine, immunosuppressive monoclonal antibodies, and CTLA4-Ig.

Claim 21 (Previously Presented): The method of Claim 20 wherein the second agent is cyclosporin A, cyclosporin G, FK-506 or monoclonal antibodies to leukocyte receptors or to their ligands.

Claim 22 (Previously Presented): The method of Claim 20 wherein the second agent is monoclonal antibodies to MHC, CD2, CD3, CD4, CD7, CD25, CD28, B7, CD45, CD58, or to ligands thereof.

Claim 23 (Previously Presented): The method of Claim 22 wherein the second agent is monoclonal antibodies to CD3.

Claim 24 (Previously Presented): The method of Claim 20 wherein the second agent is cyclosporin A.

Claim 25 (Previously Presented): The method of Claim 20 wherein the second agent is cyclosporin G.

Claim 26 (Previously Presented): The method of Claim 20 wherein the second agent is mycophenolic acid.

Claim 27 (Previously Presented): The method of Claim 20 wherein the second agent is CTLA4Ig.

Claim 28 (Previously Presented): The method of Claim 20 wherein the second agent is mycophenolate mofetil.